Galmed Pharma (GLMD) Tops Q2 EPS by 6c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. WDC
3. DECK
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. FIX

Go back to Galmed Pharma (GLMD) Tops Q2 EPS by 6c

Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results

August 6, 2020 7:00 AM EDT

TEL AVIV, Israel, Aug. 6, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol, an oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH and fibrosis, provides today updated information on the Company's scientific and clinical development programs and reports financial results for the three and six months ended June 30, 2020. The Company will host a conference call and webcast at 08:30 ET today.

... More